Mammo-50 Eligibility Queries
|
|
- Lilian Marshall
- 5 years ago
- Views:
Transcription
1 Mammo-50 Eligibility Queries Are patients who have received either neo-adjuvant or adjuvant chemo, radiotherapy or been part of another trial, ie OPTIMA, FAST FORWARD excluded from entry? Any patients are eligible provided they have had potentially curative treatment for early stage breast cancer and are disease free at three years. So therefore, any chemotherapy or radiotherapy is permitted, we will collect details on the baseline CRF. As far as Mammo-50 is concerned patients can have been in any other trial of neo-adjuvant or adjuvant treatment. It would depend on the follow-up schedule for the original trial, if they specify that patients must have annual mammography for longer than three years post-surgery then the patient would not be eligible for mammo-50. A patient was in the Poetic study 3 years ago and is now in follow up for 10 years. This patient meets all the eligibility criteria for Mammo-50 - are they able to go into Mammo-50 having been on Poetic? Yes that is fine as long as the follow up for the trial doesn t include a scheduled mammogram. After speaking with the Poetic trial team they confirmed that Poetic patients can take part in the Mammo-50 study. In the protocol it states that patients need to be 3 years post curative surgery, is it 3 years to the date or will patients be eligible if they had surgery in September and the 3 year mammogram appointment is July? The time frame for the three year mammogram is within months after surgery. In this instance if the three mammogram happens in the July before their three year surgery anniversary they would be eligible because they have received their mammogram in the 34 th month after their first therapeutic operation. This patient could not be randomised until the three year surgery anniversary date thought. However if the three year mammogram was happening in the July after the three year post surgery date this would mean the mammogram had been carried out in the patients 46 th month after their first therapeutic operation which would therefore make them ineligible. In a patients oncology notes it mentions that she had Mycosis fungoides of the right elbow. When looking at the MDT discussion regarding this they have said that this is not a cancer diagnosis, however I was under the impression that this was for lymphoma. She has received a course of course of narrow wave UVB and use Elocon ointment. She was diagnosed in 2006 and is reviewed annually with the dermatology consultants. Could confirm if this patient is eligible for Mammo-50? This patient should only enter the cohort not the main study. This is because Lymphoma is classed as a malignancy and it hasn t been 10 years since the patients diagnosis. Bowens Disease of the Breast Bowens Disease is a pre-cancerous skin lesion. On that basis the patient would be ineligible.
2 On the eligibility form for the question: No previous diagnosis of malignancy are the two sub points separate? 1-Managed by surgical treatment only and disease free for 10 years 2-Previous basal cell carcinoma of the skin or cervical intraepithelial neoplasia I m querying this because there is patient who had basal cell carcinoma 3 years ago, are they eligible? Yes the two points are separate because basal cell carcinoma is not classes as a malignancy and is benign therefore the patient is eligible to enter Mammo-50. Please can you advise on the following and if she is eligible; it s relating to the timing of mammograms. The patient had a Mx + recon etc in July Mammogram 1 took place on 20/7/12, mammogram 2 on 15/7/13, but had a third mammogram early this year in January due to pain. This is too early for the 3rd mammogram on the study. She isn't planned for another until Dec 14/Jan 15, which although inside the upper limit for entry, will technically be her 4th Mammogram. She is interested in the study, but I want to know if you would be happy with the above. Do I count the one down early as her third mammogram (but if this is the case, not eligible) Technically the one in January is her third mammogram since surgery, but was done as an investigation into symptoms so, please class the mammogram booked for Dec14/Jan15 as the patients 3 year mammogram. This will mean the patient is eligible to ether the trial. We have a patients who had breast cancer surgery in 1997 for her original cancer (she also had 5 years of Tamoxifen) and then surgery for local recurrence 3 years ago. Would the previous breast cancer deem her ineligible? Unfortunately this patient isn t eligible for Mammo-50. There are two reasons: The patient received Tamoxifen for their original cancer not just surgery The original cancer was breast cancer. Lady with a Basal Cell Carcinoma however when looked at more closely there was a mix of Basal and Squamous cells found. But diagnosis of Balsa Cell Carcinoma given This is a skin malignancy and would be outside our eligibility criteria. Squamous skin cancer or Melanoma would be excluded and therefore make the patient ineligible. Could I just check that a patient diagnosed with episodes of seborrhoeic keratosis and G1 benign neoplasm of the skin is still eligible? Because they have a benign skin or non-invasive epithelial tumour then they should be eligible. I have a patient who is interested in the Mammo 50 trial. Her surgery date was 25 Jan 2011 and her last mammogram 2 April Can she be included in the study or is she too far from her surgery date? I m sorry but the patient is too close to their four surgery date. As you are aware the latest a three year mammogram can be carried out is 8 months after the patients three year surgery date (44 months from first therapeutic operation) this is what we are also classing as our cut off for randomising/registering patients.
3 We have a potential patient who is interested in joining the trial. However we are not entirely sure if she is eligible for the trial due to the scheduling of her mammograms. Here is a short history of the patient: Had WLE on 18/Nov/2010 and a completion mastectomy in 6/Jan/2011. Patient also had Mammograms on 10/5/2012, 7/5/2013 & 6/1/2014. Because of the mammogram in 2014, we are unsure if this would be regarded as a 4 th year mammogram or because it is before November if it would be considered an intermediary mammogram. Yes this patient is eligible. Their three year mammogram date was 06/01/2014 this means the mammogram happened 38 months after their first therapeutic operation date, 18/11/2010. The eligibility criteria states that the three year mammogram needs to have been carried out between 32 and 44 months after their 1st therapeutic operation. The patient can be randomised anytime up to their four year surgery anniversary which is 18/11/2014. Before randomising this patient please can you make sure they are aware that because they had a mastectomy they may be assigned to three yearly mammograms and this could mean the patient may not be due another mammogram until Jan 2017 (three years since their last) If the patient isn t comfortable with this idea please remember that we have the Cohort Study that she could enter. I m finding quite a few ladies between 75 and 80 who would be eligible for MAMMO 50. What happens to these patients as regards to the Breast Screening Programme? We are not taking any patients out of the breast screening programme whilst they are on Mammo- 50. They will continue to receive appointments and we are just asking that they only attend for Mammo-50 mammograms during their time on the trial. Once they have finished trial treatment they should attend for screening appointments as previously. Regarding this age group I have looked on the NHSBSP website and currently only women up to the age of 70 are invited for screening although it appears there are plans to extend this to 73 by It is my understanding that this age group of women will no longer be in the breast screening programme when they are entered into the trial. Once their trial treatment has finished their frequency of mammographic follow up will be the same as for other non-trial patients in this age group and according to your own local policy. I am currently screening a lady who has had her yr3 mammo within the correct timeframe for trial entry, but for an unknown reason this lady never had a yr 2 mammo, does this make her ineligible for the trial? This patient is still eligible so long as she has had a clear three year mammogram. I am screening a lady who appears to meet all of the timeline eligibility criteria but I m not sure about her histology. This lady was diagnosed with lobular neoplasia in situ (LCIS) which has been treated the same as DCIS. Is this eligible for MAMMO-50? This patient is not eligible due to there being no evidence of a DCIS or Invasive cancer
4 I am screening a lady who had pre-op letrozole for 5 months before having her curative surgery. I think was due to having had an M.I and the drs wanted to wait 6 months post M.I before having anaesthetic. Would this affect her eligibility for MAMMO-50? I can confirm that from the information you have given this lady is eligible, we are happy for patients who have had pre-op chemotherapy or hormone treatment to enter the study. I have a patient who is eligible for Mammo 50 in all way except that, her year 3 mammo was on , and the month window following surgery was , would this make her ineligible? If the lady we spoke about had her first therapeutic operation on 06/12/2011 and her three year mammogram on 03/10/2014 this would mean the lady had her three year mammogram at around 34 months post first therapeutic operation. Which means she fits perfectly into the month window we allow for the three year mammogram to take place. Also because the ladies three year surgery anniversary date was 06/12/2014 this means she is now 37 months post her first therapeutic operation. Which means she also fits into perfectly into the month window we allow for randomisation to take place. Is a lady who has had Paget s disease eligible? The lady is following the same treatment pathway as though she has had a DCIS. Co-Chief Investigators have requested that when we have patient with Paget's disease alone the pathology report is reviewed by the Mammo-50 Co Chief Investigators. Please contact the trial office on for more information. A lady had 36mm of DCIS and when she had a WLE there were three areas of invasive cancer found within the DCIS. When the histopathology report came back one of the invasive parts was at the medial margin. The lady had radiotherapy after the WLE. The reason I m querying this ladies eligibility is because one of the inclusion criteria is: Excised invasive breast cancer with local treatment completed Does the fact that invasive cancer was found at the medial margin class as excised invasive breast cancer? I think it is down to how close the medial margin was.the National Guidance is margin should be equal to or greater than 1 mm circumferentially (ie medially). If the margin was involved or less than 1mm I think she would be ineligible as she would have a greater risk of local recurrence. Sometimes the surgeon may qualify the report on BCCOM to say the medial margin is also the anterior or skin, in which case it as acceptable and the patient gets a radiation boost.
5 I have just spoken to the patient who is very keen on the trial however she has told me that she had a breast primary 30 years ago treated with mastectomy and radiotherapy. Her DCIS was an incidental finding when she had reconstruction to her left breast and a reduction of her right in The tissue from the reduction was sent to histopathology and DCIS was found - all had been removed and she did not require any further surgery/treatment. Unfortunately this patient isn t eligible due to: The patient has had a previous breast primary. Bilateral disease (cancer removed 30 years ago was left breast incidental DCIS right breast) Treated for another malignancy with not just surgery alone (the breast cancer the lady had 30 years ago was treated with surgery and radiotherapy) We have an eligible patient for the trial who has previously been in another trial titled Supremo (Radiotherapy vs No radiotherapy) The Supremo trials team are happy for the patient to take part in the Mammo-50 trial but I wanted to check you would be happy with this? So long as the follow-up for Supremo doesn t stipulate that the lady has to have a certain mammogram schedule then she ll be eligible. A potential patient had a left mastectomy in 1994 for breast cancer, they had no radiotherapy or chemotherapy but did have Tamoxifen for 5 years. In 2012 they had a right WLE and node biopsy following a screen detected breast cancer, they had radiotherapy and is on Tamoxifen. Unfortunately this lady isn t eligible, the reasons are: This lady has had a previous breast cancer The ladies breast cancer is bilateral (left Mastectomy and right WLE) Are patients with bilateral implants eligible? We accept patients with bilateral implants, however we don t accept patents with bilateral cancer. If they lady has bilateral implants for cosmetic reasons this is fine however if she has the implants due to bilateral cancer she will not be eligible. If a patient has had Cancer in Axillary tail only are they eleigible? Unfortunately the patient we spoke about on the phone isn t eligible this is due to her not having clear evidence of a defined primary invasive breast cancer even though it has been treated this way. Also at randomisation the patients are stratified on whether they have had a WLE or mastectomy in this ladies case she s had neither so our randomisation system wouldn t be able to allocate her an arm. Patient has pleomorphic LCIS - is she eligible Pleomorphic LCIS behaves and is treated as high grade DCIS so she should be included. Classical LCIS alone is a risk factor only and should not be included.
HTA commissioned call
HTA commissioned call BACKGROUND 2002 NICE Guidance for Early Breast Cancer Discharge asymptomatic patients from hospital follow-up by 3 years. 2007 Questioning specialists attitudes to breast cancer follow-up
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report 29 BREASTSCREEN VICTORIA: ANNUAL STATISTICAL REPORT, 29 Produced by: BreastScreen Victoria Coordination Unit Level, 3 Pelham Street, Carlton South Victoria
More informationTRIAL SYNOPSIS LORIS. The Low Risk DCIS Trial. Chief Investigator. Miss Adele Francis
TRIAL SYNOPSIS LORIS Chief Investigator The Low Risk DCIS Trial Miss Adele Francis ISRCTN No. 27544579 Sponsor University of Birmingham, United Kingdom Trial Design Objectives of Feasibility Study A multi-centre,
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report 2010 BREASTSCREEN VICTORIA: ANNUAL STATISTICAL REPORT, 2010 Produced by: BreastScreen Victoria Coordination Unit Level 1, 31 Pelham Street, Carlton South
More informationChief Investigator Adele Francis University of Birmingham UK. Prof MWR Reed (CoI) University of Sheffield
The LORIS Trial: A multicentre, randomised phase III trial of standard surgery versus active monitoring in women with newly diagnosed low risk ductal carcinoma in situ. Chief Investigator Adele Francis
More informationEligibility, patient pathway & treatment. Amy Campbell Clinical Trial Coordinator
Eligibility, patient pathway & treatment Amy Campbell Clinical Trial Coordinator Trial design Eligible patients consenting to OPTIMA 4500 patients 100 UK sites 4 years recruitment Randomisation 2250 2250
More informationFaster Cancer Treatment Indicators: Use cases
Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:
More informationTable of contents. Page 2 of 40
Page 1 of 40 Table of contents Introduction... 4 1. Background Information... 6 1a: Referral source for the New Zealand episodes... 6 1b. Invasive and DCIS episodes by referral source... 7 1d. Age of the
More informationGuideline for the Management of Patients Suitable for Immediate Breast Reconstruction
Version History Guideline for the Management of Patients Suitable for Immediate Breast Reconstruction Version Summary of change Date Issued 2.0 Endorsed by the Governance Committee 20.02.08 2.1 Circulated
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report 005 Produced by: BreastScreen Victoria Coordination Unit Level, Pelham Street, Carlton South Victoria 05 PH 0 9660 6888 FX 0 966 88 EM info@breastscreen.org.au
More informationBreast Cancer Network Australia DXA bone mineral density survey May 2012
Breast Cancer Network Australia DXA bone mineral density survey May 212 I won't be having any more mineral density tests as I can't afford the high cost. Introduction Of the 14,2 women diagnosed with breast
More informationBreast Cancer Diagnosis, Treatment and Follow-up
Breast Cancer Diagnosis, Treatment and Follow-up What is breast cancer? Each of the body s organs, including the breast, is made up of many types of cells. Normally, healthy cells grow and divide to produce
More informationBREAST CANCER PATHOLOGY
BREAST CANCER PATHOLOGY FACT SHEET Version 4, Aug 2013 This fact sheet was produced by Breast Cancer Network Australia with input from The Royal College of Pathologists of Australasia I m a nurse and know
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationPaget s disease of the breast
Paget s disease of the breast This booklet is for people who d like more information about Paget s disease of the breast (also known as Paget s disease of the nipple). It describes what Paget s disease
More informationThe best treatment Your guide to breast cancer treatment in England and Wales
The best treatment Your guide to breast cancer treatment in England and Wales If you are looking for information on the treatment of secondary breast cancer (also known as advanced or metastatic breast
More informationANNEX 1 OBJECTIVES. At the completion of the training period, the fellow should be able to:
1 ANNEX 1 OBJECTIVES At the completion of the training period, the fellow should be able to: 1. Breast Surgery Evaluate and manage common benign and malignant breast conditions. Assess the indications
More informationBasement membrane in lobule.
Bahram Memar, MD Basement membrane in lobule. Normal lobule-luteal phase Normal lobule-follicular phase Lactating breast Greater than 95% are adenocarcinomas in situ carcinomas and invasive carcinomas.
More informationNHS breast screening NHS BCS Fact booklet_aw_cs4.indd 1 29/12/ :51
NHS breast screening 2 What is the aim of this leaflet? This leaflet tells you about screening for breast cancer. It aims to help you choose whether or not you take part in the NHS Breast Screening Programme.
More informationDuctal carcinoma in situ (DCIS)
Ductal carcinoma in situ (DCIS) This booklet is for people who would like more information about ductal carcinoma in situ (DCIS). It describes what DCIS is, the symptoms, how a diagnosis is made and possible
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationPhyllodes tumours: borderline and malignant
Phyllodes tumours: borderline and malignant This booklet is for people who would like more information about borderline or malignant phyllodes tumours. It describes what they are, the symptoms, how a diagnosis
More informationSurgery for Breast Cancer
Surgery for Breast Cancer 1750 Mastectomy - Petit 1894 Radical mastectomy Halsted Extended, Super radical mastectomy 1948 Modified radical mastectomy Patey 1950-60 WLE & RT Baclesse, Mustakallio 1981-85
More informationStudy Of Letrozole Extension. Coordinating Group IBCSG IBCSG BIG 1-07
tudy Of Letrozole Extension Coordinating Group IBCSG IBCSG 35-07 BIG 1-07 A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant
More informationBreastScreen Victoria Annual Statistical Report
BreastScreen Victoria Annual Statistical Report CONTENTS FIGURES AND TABLES... Figures... Tables... 3 INTRODUCTION... 5 SECTION MAXIMISING PARTICIPATION... 6 Program acceptance... 6 Eligibility... 6 Inviting
More informationGuideline for the Follow-up of Patients with Gynaecological Malignancies
Guideline for the Follow-up of Patients with Gynaecological Malignancies Version History Version Date Summary of Change/Process 2.0 20.02.08 Endorsed by the Governance Committee 2.1 18.11.10 Circulated
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationDuctal Carcinoma-in-Situ: New Concepts and Controversies
Ductal Carcinoma-in-Situ: New Concepts and Controversies James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS Case Presentation
More informationNHS breast screening Helping you decide
NHS breast screening Helping you decide 1 What is breast cancer? 2 What is breast screening? 3 Breast screening results 6 Making a choice the possible benefits 9 and risks of breast screening What are
More informationWhat is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine
What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine What is Cancer? Layman s terms: cancer starts when cells grow out of control (in any place in the body) and crowd out normal cells
More informationBreastScreen Aotearoa Annual Report 2015
BreastScreen Aotearoa Annual Report 2015 EARLY AND LOCALLY ADVANCED BREAST CANCER PATIENTS DIAGNOSED IN NEW ZEALAND IN 2015 Prepared for Ministry of Health, New Zealand Version 1.0 Date November 2017 Prepared
More informationBreast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate surgical options
A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Breast cancer reconstruction surgery (immediate and delayed) across Ontario: Patient indications and appropriate
More informationNCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham. Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence
NCIN Breast Cancer Workshop 13 March 2014 Hilton Metropole, NEC, Birmingham Kieran Horgan, Dick Rainsbury, Mark Sibbering, Gill lawrence 1 Interactive Workshop Session Professor Kieran Horgan Workshop
More informationQuality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care
Quality ID #263: Preoperative Diagnosis of Breast Cancer National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process DESCRIPTION:
More informationBreast Cancer Screening and Treatment Mrs Belinda Scott Breast Surgeon Breast Associates Auckland
Breast Cancer Screening and Treatment 2009 Mrs Belinda Scott Breast Surgeon Breast Associates Auckland BREAST CANCER THE PROBLEM 1.1 million women per year 410,000 deaths each year Increasing incidence
More informationEducational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery
Educational Goals and Objectives for Rotations on: Breast, Wound and Plastic Surgery Goal The goal of the Breast Surgery rotation is to develop the knowledge, skills and attitudes necessary to evaluate,
More informationCASEFINDING. KCR Abstractor s Training
CASEFINDING KCR Abstractor s Training 1 Introduction Casefinding Definition Purpose Methods Sources vs Resources Reportable Cancer Conditions Non-Reportable Conditions Ambiguous Terminology 2 https://www.google.com/search?q=puzzle+pieces&client=firefox-a&hs=mdc&rls=org.mozilla
More informationMy Personalized Breast Cancer Worksheet
My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect
More informationSOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT
SOUTH EAST SCOTLAND CANCER NETWORK PROSPECTIVE CANCER AUDIT BREAST CANCER 2013 COMPARATIVE AUDIT REPORT Mr Glyn Neades Chair Breast Group and Consultant Surgeon, NHS Fife Mr Matthew Barber, Consultant
More informationProgramme Report
Programme Report 2015-2016 Contents Introduction from the Head of Screening, National Screening Service 2 Highlights of 2015-2016 4 Programme report 5 References 19 Introduction from the Head of Screening,
More informationTypes of Breast Cancer
IOWA RADIOLOGY 1 Types of Breast Cancer 515-226-9810 Ankeny Clive Downtown Des Moines IOWA RADIOLOGY 1 Table of Contents Introduction... 1 Ductal Carcinoma... 2 Paget s Disease of the Nipple... 8 Lobular
More informationBreast Cancer. For breast cancer, the mortality risk varies with the stage of the cancer.
CREATED EXCLUSIVELY FOR FINANCIAL PROFESSIONALS Rx FOR SUCCESS Breast Cancer Breast cancer is the most common cancer in women in the United States and second only to lung cancer as a cause of cancer deaths.
More informationRUTGERS CANCER INSTITUTE OF NEW JERSEY - ROBERT WOOD JOHNSON MEDICAL SCHOOL INTERDISCIPLINARY BREAST SURGERY FELLOWSHIP CORE EDUCATIONAL OBJECTIVES
RUTGERS CANCER INSTITUTE OF NEW JERSEY - ROBERT WOOD JOHNSON MEDICAL SCHOOL INTERDISCIPLINARY BREAST SURGERY FELLOWSHIP CORE EDUCATIONAL OBJECTIVES At the completion of Breast Fellowship training, the
More informationsurgery choices For Women with Early-Stage Breast Cancer family EDUCATION PATIENT
surgery choices For Women with Early-Stage Breast Cancer PATIENT & family EDUCATION U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute As a woman with
More informationNHS breast screening Helping you decide
NHS breast screening Helping you decide What is breast cancer?... 3 What is breast screening?... 4 Breast screening results... 7 Making a choice the possible benefits and risks of breast screening... 11
More informationNHS breast screening Helping you decide
NHS breast screening Helping you decide What is breast cancer?... 3 What is breast screening?... 3 Breast screening results... 5 Making a choice the possible benefits and risks of breast screening... 8
More informationWaikato Breast Cancer Register March 2010
Waikato Breast Cancer Register March 2010 Demographics - Population: Total New Waikato Breast Cancers Diagnosed 2005 2008 1072 Total Patients Eligible for WBCR 1008 Total Records Entered into WBCR (95%
More information4 Call our Helpline on
Lobular neoplasia This booklet is about lobular neoplasia, which includes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS). It explains how it is diagnosed and treated. This information
More informationInterval Cancers in BreastScreen Aotearoa
Interval Cancers in BreastScreen Aotearoa 2008 2009 Released 2018 nsu.govt.nz Citation: National Screening Unit. 2018. Interval Cancers in BreastScreen Aotearoa 2008 2009. Wellington: Ministry of Health.
More informationPublic Health Agency NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN QUALITY ASSURANCE REFERENCE CENTRE
Public Health Agency Improving Your Health and Wellbeing NORTHERN IRELAND BREAST SCREENING PROGRAMME ANNUAL REPORT & STATISTICAL BULLETIN 2010-2011 QUALITY ASSURANCE REFERENCE CENTRE August 2012 1 2 Contents
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationBreast Thermography A radiation-free breast health assessment suitable for young women By Janet van Dam Medical Thermographer/ Member ACCT
Breast Thermography A radiation-free breast health assessment suitable for young women By Janet van Dam Medical Thermographer/ Member ACCT I often get the question: at what age should I start worrying
More informationCase Scenario 1 History and Physical 3/15/13 Imaging Pathology
Case Scenario 1 History and Physical 3/15/13 The patient is an 84 year old white female who presented with an abnormal mammogram. The patient has a five year history of refractory anemia with ringed sideroblasts
More informationImaging the Symptomatic Patient. Avice M.O Connell MD,FACR,FSBI Professor of Imaging Sciences Director, Women s Imaging University of Rochester
Imaging the Symptomatic Patient Avice M.O Connell MD,FACR,FSBI Professor of Imaging Sciences Director, Women s Imaging University of Rochester The four most common symptoms Mass Pain Discharge Infection
More informationNational Breast Cancer Audit next steps. Martin Lee
National Breast Cancer Audit next steps Martin Lee National Cancer Audits Current Bowel Cancer Head & Neck Cancer Lung cancer Oesophagogastric cancer New Prostate Cancer - undergoing procurement Breast
More informationPodcast ESMO 2011: The Tamoxifen- Exemestane Adjuvant Multinational (TEAM) Phase III Breast Cancer Trial Results
Page 1 of 7 Contact EJCMO.tv Blog» Editorial Board The EJCMO Medical Journal About EJCMO.tv Sub-Specialties» Podcast ESMO 2011: The Tamoxifen- Exemestane Adjuvant Multinational (TEAM) Phase III Breast
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationLessons Learnt from Neoadjuvant Hormone Therapy. Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationLessons Learnt from Neoadjuvant Hormone Therapy. 10 Lessons Learnt from Neoadjuvant Endocrine Therapy. Lesson 1
Lessons Learnt from Neoadjuvant Hormone Therapy Mike Dixon Clinical Director Breakthrough Research Unit Edinburgh 10 Lessons Learnt from Neoadjuvant Endocrine Therapy 10 Lessons Learnt from Neoadjuvant
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationMasDA Mastectomy Decisions Audit 2015
MasDA Mastectomy Decisions Audit 2015 AUDIT PROTOCOL FULL TITLE Mastectomy Decisions Audit: a prospective, multi-centre, population-based audit SHORT TITLE MasDA CHIEF INVESTIGATORS Mrs Jagdeep K Singh,
More informationCase Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity.
Case Scenario 1: This case has been slightly modified from the case presented during the live session to add clarity. Background: 46 year old married premenopausal female with dense breasts has noticed
More informationBreast Screening: risks if you do and risks if you don t. Stephen W. Duffy Wolfson Institute of Preventive Medicine
Breast Screening: risks if you do and risks if you don t Stephen W. Duffy Wolfson Institute of Preventive Medicine General principle There is often discussion of benefits and harms of breast screening
More informationLesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node
Lesion Imaging Characteristics Mass, Favoring Benign Circumscribed Margins Intramammary Lymph Node Oil Cyst Mass, Intermediate Concern Microlobulated Margins Obscured Margins Mass, Favoring Malignant Indistinct
More informationClinical Trial Results Database Page 1
Page 1 Sponsor Novartis UK Limited Generic Drug Name Letrozole/FEM345 Therapeutic Area of Trial Localized ER and/or PgR receptor positive breast cancer Study Number CFEM345EGB07 Protocol Title This study
More informationUnexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience
Unexplained National Differences in the Management of DCIS Revealed by Audit: the Sloane Project Experience NCIN Annual Conference, National Motorcycle Museum June 2008 Dr Gill Lawrence West Midlands Cancer
More informationScreening Mammography: The Controversy, Risk Assessment and Individualized Screening recommendations. Jonathan T. Sims MD, MBA
Screening Mammography: The Controversy, Risk Assessment and Individualized Screening recommendations. Jonathan T. Sims MD, MBA I have no relevant Financial Disclosures Agenda Discuss the recent studies
More informationHealth Bites Breast Cancer. Breast Cancer. Normal breast
Health Bites Breast Cancer Breast Cancer Normal breast The normal breast tissue varies in size and shape. The breasts rest in front of the rib cage. The breasts are made up of fatty tissue, milk ducts
More informationGuideline for the Diagnosis of Breast Cancer
Guideline for the Diagnosis of Breast Cancer Version History Version Date Brief Summary of Change Issued 2.0 May 2007 Approved by the Governance Committee 2.0 25.11.08 Discussed at the NSSG 2.1 5.12.08
More informationThis information explains the advice about familial breast cancer (breast cancer in the family) that is set out in NICE guideline CG164.
Familial breast cancer (breast cancer in the family) Information for the public Published: 1 June 2013 nice.org.uk About this information NICE guidelines provide advice on the care and support that should
More informationYou can also complete the survey over the phone with a trained interviewer by calling the study team toll free at
Last modified: 0//08 0:0:5 AM Thank you very much for your participation in this important study. If you prefer, you can complete this survey online at www.stjude.org/ltfu-ask8. Your log-in ID is your
More informationBreast Health Programme at S.G.P.G.I.
Breast Health Programme at S.G.P.G.I. The first decade Department of Endocrine Surgery Br.H.P.: Components Breast Clinic Surgery Resident training Research Community Education/ Awareness Br.H.P.: Clinical
More informationBREAST MRI. Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School
BREAST MRI Elizabeth A. Rafferty, M.D. Avon Comprehensive Breast Center Massachusetts General Hospital Harvard Medical School BREAST MRI Any assessment of the breast parenchyma requires the administration
More informationCase #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ).
SOLID TUMORS WORKSHOP Cases for review Prostate Cancer Case #1: 75 y/o Male (treated and followed by prostate cancer oncology specialist ). January 2009 PSA 4.4, 20% free; August 2009 PSA 5.2; Sept 2009
More informationControversies in Breast Cancer
I Have Breast Cancer Now What? Katherine Gale FRACS Oncoplastic Breast Surgeon Controversies in Breast Cancer Katherine Gale FRACS Oncologic Controversies Margins in BCS Nipple Sparing Mastectomy:? Safe
More informationThe Case FOR Oncoplastic Surgery in Small Breasts. Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA
The Case FOR Oncoplastic Surgery in Small Breasts Barbara L. Smith, MD, PhD Massachusetts General Hospital Harvard Medical School Boston, MA USA Changing issues in breast cancer management Early detection
More informationAttending Physician Statement- Cancer or Carcinoma in-situ
Instruction to doctor: This patient is insured with us against the happening of certain contingent events associated with his health. A claim has been submitted in connection with Cancer or Carcinoma in-situ.
More informationBreast Imaging! Ravi Adhikary, MD!
Breast Imaging! Ravi Adhikary, MD! ACS Estimated Cancers Statistics 2014! Breast! New Cases in Women! 232,670 (+67,570 in situ)! Deaths in Women! 40,000! Colon! 48,380! 24,040! Cervical! 12,360! 4,020!
More informationSingle Suspected Cancer Pathway Definitions pathway start date
Single Suspected Cancer Pathway Definitions pathway start date Date: December 2018 Version: 8.0 Wales Cancer Owner: Network and Welsh Government Status Draft 1 P a g e Purpose of Document This document
More informationClinical Trials of Proton Therapy for Breast Cancer. Andrew L. Chang, MD 張維安 Study Chair
Clinical Trials of Proton Therapy for Breast Cancer Andrew L. Chang, MD 張維安 Study Chair AndrewLChangMD@gmail.com Disclosure Proton Center Development Corporation Scripps San Diego Proton Therapy Center
More informationFAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions
ULast updated: 09/02/2015 Protocol 3 BRCA mutation carrier guidelines Frequently asked questions UQ: How accurate are the remaining lifetime and 5 year breast cancer risks in the table? These figures are
More informationMammographic imaging of nonpalpable breast lesions. Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand
Mammographic imaging of nonpalpable breast lesions Malai Muttarak, MD Department of Radiology Chiang Mai University Chiang Mai, Thailand Introduction Contents Mammographic signs of nonpalpable breast cancer
More informationBreast Cancer. Common kinds of breast cancer are
Breast Cancer A breast is made up of three main parts: glands, ducts, and connective tissue. The glands produce milk. The ducts are passages that carry milk to the nipple. The connective tissue (which
More informationWhen do you need PET/CT or MRI in early breast cancer?
When do you need PET/CT or MRI in early breast cancer? Elizabeth A. Morris MD FACR Chief, Breast Imaging Service Memorial Sloan-Kettering Cancer Center NY, NY Objectives What is the role of MRI in initial
More informationImage guided core biopsies:
Recommendations on the Surgical, Radiologic and Pathologic Approaches to Breast Disease: Using best practices based on multidisciplinary methodologies developed through the Allina Breast Committee. Image
More informationYour Guide to the Breast Cancer Pathology. Report. Key Questions. Here are important questions to be sure you understand, with your doctor s help:
Your Guide to the Breast Cancer Pathology Report Key Questions Here are important questions to be sure you understand, with your doctor s help: Your Guide to the Breast Cancer Pathology Report 1. Is this
More informationContralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks
Contralateral Prophylactic Mastectomy with Immediate Reconstruction: Added Benefits, Added Risks Grant W. Carlson Wadley R. Glenn Professor of Surgery Divisions of Plastic Surgery & Surgical Oncology Emory
More informationSurgery Choices for Breast Cancer
Surgery Choices for Breast Cancer Surgery Choices for Women with DCIS or Breast Cancer As a woman with DCIS (ductal carcinoma in situ) or breast cancer that can be removed with surgery, you may be able
More informationHereditary Cancer Risk Program
Hereditary Cancer Risk Program Family History and Risk Assessment Questionnaire Please answer questions to the best of your ability in order to help us establish your risk assessment. Write in unk (unknown)
More informationAppendix ZOOM Etude pour site internet
Appendix ZOOM Etude pour site internet Indication Traitement adjuvant pour des patients présentant une mutation germinale des gènes BRCA1/2 et un risque élevé de cancer du sein primaire HER2 négatif Title
More informationOncology Report to the Community. Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital
Oncology Report to the Community Northwestern Medicine Central DuPage Hospital and Northwestern Medicine Delnor Hospital 1 Contents Letter from Leadership.... 1 Survivorship: Life After Cancer Treatment....
More informationSurgical Therapy: Sentinel Node Biopsy and Breast Conservation
Surgical Therapy: Sentinel Node Biopsy and Breast Conservation Stephen B. Edge, MD Professor of Surgery and Oncology Roswell Park Cancer Institute University at Buffalo Dr. Roswell Park: Tradition in Cancer
More informationRadiation Treatment for Breast. Cancer. Melissa James Radiation Oncologist August 2015
Radiation Treatment for Breast Cancer Melissa James Radiation Oncologist August 2015 OUTLINE External Beam Radiation treatment. (What is Radiation, doctor?) Role of radiation. (Why am I getting radiation,
More informationSOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT
SOUTH EAST SCOTLAND CANCER NETWORK (SCAN) PROSPECTIVE CANCER AUDIT BREAST CANCER 2016 COMPARATIVE AUDIT REPORT Mr Glyn Neades Chair SCAN Breast Group and Consultant Surgeon, NHS Fife & NHS Lothian Mr Ahmed
More informationBenign phyllodes tumour
Benign phyllodes tumour This leaflet tells you about benign phyllodes tumours. It explains what a benign phyllodes tumour is, and how it is diagnosed and treated. Benign breast conditions information provided
More informationPromise of a beautiful day
Promise of a beautiful day Ductal carcinoma in Situ Lobular Carcinoma in Situ Natural History Manosmed Tartous Oct 2009 Gérard ABADJIAN MD Pathology Department Hôtel-Dieu de France. Associate Professor
More informationFormat Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te
Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format
More informationAngela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008
Angela Gilliam, MD University of Colorado Surgical Grand Rounds November 3, 2008 Breast Cancer Most common cancer in American women 180,000 new cases per year Second most common cause of cancer death 44,000
More informationBreast MRI: Friend or Foe?
Breast : Friend or Foe? APPLEGATE HAS DOUBLE MASTECTOMY IN CANCER SCARE DIAGNOSED WITH CANCER IN ONE BREAST Comments: 0 ASSOCIATED PRESS 8/19/2008 UCSF Postgraduate Course March 19, 2009 E. Shelley Hwang
More informationLOBULAR CARCINOMA IN SITU: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE
: WHAT DOES IT MEAN? THE SURGEON'S PERSPECTIVE Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University of Washington Joint Member, Fred Hutchinson Cancer
More information